Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$630.6m

Verve Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sek Kathiresan

Chief executive officer

US$9.3m

Total compensation

CEO salary percentage6.4%
CEO tenure5yrs
CEO ownership0.8%
Management average tenure2.7yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Jul 12
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate

Why Verve Therapeutics Deserves A Spot On Your Watchlist

Jun 13

Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

May 14
Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher

The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12
The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Nov 09
We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics: Cathie Wood Adds To ARKK

Sep 20

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Aug 23

Verve Therapeutics falls postmarket on $200M stock offering

Jul 20

More CRISPR In Human Subjects

Jul 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31
Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

CEO Compensation Analysis

How has Sek Kathiresan's remuneration changed compared to Verve Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$197m

Dec 31 2023US$9mUS$597k

-US$200m

Sep 30 2023n/an/a

-US$193m

Jun 30 2023n/an/a

-US$192m

Mar 31 2023n/an/a

-US$179m

Dec 31 2022US$8mUS$571k

-US$157m

Sep 30 2022n/an/a

-US$148m

Jun 30 2022n/an/a

-US$125m

Mar 31 2022n/an/a

-US$137m

Dec 31 2021US$6mUS$519k

-US$120m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$99m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$2mUS$480k

-US$46m

Compensation vs Market: Sek's total compensation ($USD9.32M) is above average for companies of similar size in the US market ($USD3.23M).

Compensation vs Earnings: Sek's compensation has increased whilst the company is unprofitable.


CEO

Sek Kathiresan (52 yo)

5yrs

Tenure

US$9,319,782

Compensation

Dr. Sekar Kathiresan, M.D., also known as Sek, is Independent Director at Relay Therapeutics, Inc. since July 2022. He is a Founder at Maze Therapeutics, Inc and Director from September 2022. He is Co-Foun...


Leadership Team

NamePositionTenureCompensationOwnership
Sekar Kathiresan
Co-Founder5yrsUS$9.32m0.80%
$ 5.1m
Allison Dorval
CFO & Principal Accounting Officer2.7yrsUS$3.48m0.0048%
$ 30.5k
Andrew Ashe
President5.9yrsUS$3.32m0.41%
$ 2.6m
Kiran Musunuru
Co-Founderno datano datano data
J. Joung
Co-Founderno datano datano data
Anthony Philippakis
Co-Founder & Scientific Advisory Board Memberno dataUS$7.97kno data
Barry Ticho
Co-Founderno datano datano data
Issi Rozen
Co-Founder & Strategic Advisorno datano datano data
Troy Lister
Chief Scientific Officerless than a yearno data0.0021%
$ 13.5k
Joan Nickerson
Chief Administrative Officer1.4yrsno data0.010%
$ 65.0k
Jennifer Robinson
Vice President of Investor Relations & Corporate Communications2.7yrsno datano data
Kaitlin Duffy
Executive Director of Human Resources1.4yrsno datano data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Management: VERV's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sekar Kathiresan
Co-Founder5yrsUS$9.32m0.80%
$ 5.1m
Anthony Philippakis
Co-Founder & Scientific Advisory Board Member2.8yrsUS$7.97kno data
Burt Adelman
Co-Founder & Independent Chairman of the Board6.4yrsUS$451.88k0.51%
$ 3.2m
Daniel Rader
Member of Scientific Advisory Boardno datano datano data
Eugene Braunwald
Member of Scientific Advisory Boardno datano datano data
Michael MacLean
Independent Director3.2yrsUS$521.07k0%
$ 0
Sheila Mikhail
Independent Director3.3yrsUS$412.38k0%
$ 0
Lonnel Coats
Independent Director1.9yrsUS$407.38k0%
$ 0
Jodie Morrison
Directorless than a yearno datano data
Krishna Yeshwant
Independent Director5.9yrsUS$410.88k0%
$ 0
Alexander Cumbo
Independent Director2.1yrsUS$405.88k0%
$ 0
Andrew Geall
Member of Scientific Advisory Boardno datano datano data

3.2yrs

Average Tenure

54.5yo

Average Age

Experienced Board: VERV's board of directors are considered experienced (3.2 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.